期刊
TRENDS IN IMMUNOLOGY
卷 39, 期 12, 页码 1005-1020出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2018.10.010
关键词
-
类别
资金
- NIH [AR067763, CA190449]
- Medicine by Design/Canada First Research Excellence Fund (TLM) [C1TPA-2016-20]
- NATIONAL CANCER INSTITUTE [R01CA190449] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR067763] Funding Source: NIH RePORTER
The aryl hydrocarbon receptor (AhR) is a cytoplasmic receptor and transcription factor activated through cognate ligand binding. It is an important factor in immunity and tissue homeostasis, and structurally diverse compounds from the environment, diet, microbiome, and host metabolism can induce AhR activity. Emerging evidence suggests that AhR is a key sensor allowing immune cells to adapt to environmental conditions and changes in AhR activity have been associated with autoimmune disorders and cancer. Furthermore, AhR agonists or antagonists can impact immune disease outcomes identifying AhR as a potentially actionable target for immunotherapy. In this review, we describe known ligands stimulating AhR activity, downstream proinflammatory and suppressive mechanisms potentiated by AhR, and how this understanding is being applied to immunopathology to help control disease outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据